Type 1 diabetes (T1D) is a chronic autoimmune disease in which the immune system selectively destroys the insulin-producing beta cells of the pancreatic islets. Despite decades of research and significant advances in glucose monitoring and insulin delivery, a true cure remains elusive. The disease imposes a lifelong burden of constant vigilance, injections, and risk of complications. Recent breakthroughs in high-throughput technologies have given rise to multi-omics approaches—integrative analyses of the genome, transcriptome, proteome, metabolome, and beyond. By layering these biological data sets, researchers can now map the complex molecular choreography that leads to beta cell destruction and, crucially, identify novel targets for intervention. This article examines how multi-omics is accelerating the search for a T1D cure, highlighting key findings and promising future directions.

Understanding Multi-omics Approaches

Multi-omics refers to the simultaneous or sequential analysis of multiple biological “omes”—the complete sets of molecules that define a cell, tissue, or organism at a given time. Rather than studying each layer in isolation, multi-omics integrates data across these domains to reveal interactions, causal networks, and emergent properties that single-omic studies miss. The core omics layers relevant to T1D research include:

  • Genomics: The study of an individual’s complete DNA sequence, including variations such as single nucleotide polymorphisms (SNPs), insertions, and deletions. In T1D, genomics has pinpointed risk loci like HLA, INS, PTPN22, and CTLA-4.
  • Epigenomics: The map of chemical modifications to DNA and histone proteins that regulate gene expression without altering the underlying sequence. DNA methylation patterns, for instance, differ between T1D patients and healthy controls, especially in immune-related genes.
  • Transcriptomics: The measurement of RNA transcripts—both coding (mRNA) and non-coding (e.g., microRNAs, lncRNAs)—providing a snapshot of which genes are active. Single-cell RNA sequencing has become a powerful tool to study heterogeneity among beta cells and infiltrating immune cells.
  • Proteomics: The large-scale study of proteins, including their abundance, post-translational modifications, and interactions. Autoantibodies to insulin, GAD65, IA-2, and ZnT8 are classic proteomic markers of T1D, but newer approaches are uncovering less obvious protein targets.
  • Metabolomics: The comprehensive profiling of small molecule metabolites (e.g., amino acids, lipids, glucose intermediates). Metabolic perturbations often precede overt autoimmunity and offer early biomarkers.
  • Microbiomics: Analysis of the gut microbial community, which influences immune system development and has been linked to T1D risk through effects on molecular mimicry, short-chain fatty acid production, and barrier integrity.

Integration of these layers—often combined with clinical data, lifestyle factors, and longitudinal samples—allows researchers to construct systems-level models of T1D pathogenesis. For example, a genomic variant may increase risk only when certain environmental conditions (e.g., viral infection, dietary factors) trigger epigenetic changes that alter transcriptomic profiles in immune cells, ultimately leading to proteomic and metabolomic signatures of beta cell stress. Multi-omics captures these cascading effects.

The Role of Multi-omics in T1D Research

Genomics and Genetic Susceptibility

The genetic architecture of T1D has been extensively characterized through genome-wide association studies (GWAS) and fine-mapping efforts. More than 60 risk loci have been identified, with the HLA region on chromosome 6p21 accounting for about 40–50% of heritable risk. However, knowing the genetic variants is only the first step. Multi-omics studies have revealed how these variants affect downstream molecular processes. For instance, risk variants in the INS gene alter the expression of insulin mRNA in the thymus, reducing central tolerance. Similarly, variants in PTPN22 affect protein tyrosine phosphatase activity, influencing T-cell receptor signaling thresholds. Integrating genomics with transcriptomics and epigenomics has clarified that many T1D risk SNPs lie in non-coding regulatory regions, where they affect enhancer activity and chromatin accessibility in specific immune cell types (Nature, 2019).

Epigenetics and Environmental Triggers

Epigenetic marks provide a bridge between genetic predisposition and environmental exposures. The TEDDY study (The Environmental Determinants of Diabetes in the Young) has collected longitudinal blood samples from at-risk children and performed genome-wide DNA methylation profiling. These data have identified differentially methylated regions (DMRs) associated with future seroconversion to autoantibody positivity. For example, hypomethylation of the INS gene promoter in peripheral blood cells has been observed in children who later develop T1D, suggesting that epigenetic dysregulation of insulin expression in immune cells may precede autoimmunity. Similarly, viral infections (e.g., enteroviruses) can induce epigenetic changes in pancreatic islets that attract immune attack (Diabetes, 2021).

Transcriptomics: From Bulk to Single-Cell Resolution

Bulk transcriptomics of peripheral blood mononuclear cells (PBMCs) and pancreatic tissue has long been used to identify gene expression signatures of T1D. However, the advent of single-cell RNA-sequencing (scRNA-seq) has revolutionized the field. By profiling thousands of individual cells from human pancreatic islets and draining lymph nodes, researchers have discovered rare beta cell subtypes that are more resistant to stress, as well as novel T-cell populations that drive beta cell destruction. For instance, scRNA-seq studies have revealed that in T1D, resident memory CD8+ T cells (TRM) persist within islets and express cytolytic molecules like granzyme B and perforin. Targeting these cells or their recruitment signals represents a new therapeutic opportunity (Cell, 2019). Transcriptomics also highlights the role of interferons and the unfolded protein response in beta cell dysfunction.

Proteomics: Beyond Autoantibodies

Proteomics in T1D has traditionally focused on autoantibodies, which are the gold standard for risk prediction. However, mass spectrometry-based proteomics now allows unbiased identification of proteins that are differentially expressed or modified in T1D. For example, a 2022 study analyzed the serum proteome of children progressing to T1D and found elevated levels of proteins involved in complement activation, coagulation, and extracellular matrix remodeling years before clinical onset. Some of these proteins (e.g., C3, SERPINA1) may serve as new biomarkers or even targets for intervention. Proteomics of pancreatic islets has also identified neoantigens—post-translationally modified self-proteins—that may trigger autoimmune responses. For instance, deamidated insulin peptides and hybrid insulin peptides (HIPs) are recognized by autoreactive T cells, and blocking their formation or presentation could be a therapeutic strategy (JCI Insight, 2020).

Metabolomics and the Preclinical Window

Metabolomic profiling of children who later develop T1D has uncovered metabolic changes that occur months to years before autoantibodies appear. These include altered levels of branched-chain amino acids, lipids (e.g., phospholipids, triglycerides), and gut-microbiota-derived metabolites such as short-chain fatty acids. A 2019 study from the DIPP study in Finland reported that children who progress to T1D have a distinct serum metabolome as early as age 3 months, suggesting a very early metabolic dysregulation. Integration with microbiomics has shown that infants with lower microbial diversity and fewer butyrate-producing bacteria have a higher risk of islet autoimmunity. Such multi-omic signatures could enable earlier screening and intervention—perhaps even before the immune system becomes fully activated.

Key Findings: New Targets for Therapy

Immune Checkpoints and Regulatory T Cells

Multi-omics analyses have pinpointed dysregulated immune checkpoint molecules and impaired regulatory T cell (Treg) function as central to T1D pathogenesis. Transcriptomic studies of Tregs from T1D patients show reduced expression of IL-2 receptor alpha (CD25) and FoxP3, alongside increased expression of pro-inflammatory cytokines. Proteomics has identified altered phosphorylation of key signaling nodes (e.g., STAT5) in Tregs. These findings support the development of therapies that boost Treg numbers or function—such as low-dose IL-2 therapy, which has shown promise in early clinical trials. Another checkpoint molecule under investigation is PD-1; its ligand PD-L1 is expressed on beta cells and may protect against autoimmune attack. Enhancing PD-L1 expression on beta cells or using PD-1 agonists could re-establish immune tolerance.

Beta Cell Stress and Neoepitopes

Integrative multi-omics has revealed that beta cells are not passive victims but actively contribute to their own demise. Under stress (e.g., from high glucose, ER stress, or viral infection), beta cells can post-translationally modify self-proteins, creating neoepitopes that are recognized by T cells. For example, hybrid insulin peptides (HIPs) fuse fragments of insulin with other secretory granule proteins like neuropeptide Y. Proteomics has identified dozens of such HIPs, and T-cell responses to them are present in T1D patients. Therapeutically, blocking the formation of these neoepitopes—or using tolerogenic vaccines that induce immune tolerance to them—could prevent progression. Multi-omics is also revealing the role of the type I interferon signature in beta cells; inhibiting interferon signaling with JAK inhibitors (e.g., baricitinib) has shown clinical benefit in newly diagnosed T1D.

Retroviral Elements and Innate Immunity

Genomic and transcriptomic studies have identified expression of endogenous retroviruses (ERVs) in pancreatic islets of T1D patients. These ancient viral sequences, normally silenced, can become reactivated under inflammatory conditions, producing double-stranded RNA that triggers antiviral innate immune responses. The PRR sensors (e.g., MDA5, RIG-I) and downstream interferon pathways represent potential drug targets. The discovery that T1D risk variants in the IFIH1 gene (encoding MDA5) alter response to ERV-derived dsRNA strengthens the link. Modulating this pathway—perhaps with drugs that inhibit MDA5 or its downstream signaling—could reduce the initial triggering of autoimmunity.

Metabolic Enzyme Targets

Metabolomics has highlighted enzymes in the lipid metabolism pathways that may be druggable. For instance, levels of ceramides are elevated in T1D patients and may contribute to beta cell apoptosis. Inhibiting serine palmitoyltransferase (the first enzyme in ceramide synthesis) protects beta cells in animal models. Similarly, the enzyme 12-lipoxygenase (12-LOX) produces pro-inflammatory eicosanoids in beta cells; 12-LOX inhibitors have entered clinical trials for T1D. Multi-omic integration helps prioritize these targets by showing that their expression and activity correlate with disease stage and immune infiltration.

Challenges and Integration Strategies

While multi-omics offers unprecedented power, it also presents significant challenges. First, data heterogeneity: each omics layer uses different platforms, units, and batch effects. Statistical integration methods—such as multivariate analysis (e.g., MOFA, DIABLO), network-based approaches (e.g., WGCNA, Bayesian networks), and machine learning (e.g., random forests, deep learning)—are required to merge data sets meaningfully. Second, sample availability: human pancreatic tissue is scarce, and most studies rely on organ donor programs or biopsies. This limits sample size and temporal resolution. Longitudinal multi-omics using blood, stool, and occasional biopsy is feasible only in large consortia like TEDDY and TrialNet. Third, causality: multi-omics associations are often correlative. Validation requires perturbation experiments in cell models, organoids, or animal models. For example, if proteomics identifies a candidate protein, knocking it down in a beta cell line and measuring effects on apoptosis and immune activation is essential.

Computational pipelines that handle missing data, normalize across platforms, and integrate prior knowledge are rapidly maturing. Cloud-based platforms and public repositories (e.g., the EBI Multi-Omics Database, the T1D Knowledge Portal) enable researchers to share and query multi-omic data. The use of causal inference algorithms (e.g., Mendelian randomization using genomic instruments) can help infer directionality from cross-sectional omics data.

Future Directions in T1D Research

Personalized Therapies

The ultimate goal of multi-omics is to stratify patients into subgroups—or “endotypes”—that respond to specific interventions. For instance, some patients may have a strong genetic component (e.g., high-risk HLA haplotypes) while others have a predominant environmental trigger (e.g., enterovirus-associated). Multi-omics could inform which patients are likely to benefit from Treg-boosting therapies, JAK inhibitors, or antigen-specific tolerance. Clinical trials are already beginning to incorporate omics-based stratification to enrich for responders.

Liquid Biopsies and Early Detection

Blood-based multi-omics—combining circulating cell-free DNA methylation (for beta cell death), microRNA panels (for immune activation), and proteomic/metabolomic markers—may enable detection of insulitis non-invasively years before symptoms appear. Such a “T1D early warning test” would dramatically reduce the burden of trials and open the door to preventive therapies. The Beyond Type 1 Research Group is actively pursuing such liquid biopsy approaches.

Computational Modeling and AI

Machine learning models that integrate multi-omics data with clinical parameters can predict disease progression with increasing accuracy. Deep learning architectures (e.g., autoencoders, graph neural networks) can learn representations that capture nonlinear interactions between omics layers. These models may identify combinations of targets that are synergistic for therapy. For example, a model might predict that a combination of a JAK inhibitor and a Treg booster is more effective than either alone, and this could be tested in preclinical systems.

From Bench to Bedside

Several multi-omics-derived targets are already in clinical development. Baricitinib (a JAK1/JAK2 inhibitor) has completed a phase 2 trial showing preservation of C-peptide in new-onset T1D. Low-dose IL-2 (aldesleukin) is in phase 3 trials for T1D. A tolerogenic DNA vaccine targeting proinsulin (BHT-3021) was developed based on epitope discovery from proteomics and transcriptomics. As multi-omics platforms become cheaper and faster, the pace of target discovery will accelerate, and we can expect a pipeline of new agents targeting immune checkpoints, metabolic enzymes, and viral sensors.

Conclusion

The use of multi-omics approaches in type 1 diabetes research has moved beyond mere description to actionable discovery. By integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, scientists are building a comprehensive molecular picture of how T1D begins and progresses. This systems-level view has unveiled new therapeutic targets that were invisible to earlier single-omic studies—from immune checkpoints and neoepitopes to retroviral elements and metabolic enzymes. While challenges of data integration, sample availability, and causal validation remain, the trajectory is clear: multi-omics is accelerating the quest for a cure. The next decade will likely see the translation of these discoveries into personalized, targeted therapies that can halt or reverse T1D, bringing hope to millions living with the disease.